These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1416 related items for PubMed ID: 28043907

  • 1. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND.
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 4. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND.
    Chest; 2016 Dec 13; 150(6):1302-1312. PubMed ID: 27938741
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW, Svanström H, Lund M, Pasternak B, Melbye M.
    Int J Cardiol; 2018 Oct 01; 268():113-119. PubMed ID: 29934230
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 01; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 7. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L.
    Curr Med Res Opin; 2017 Sep 01; 33(9):1595-1604. PubMed ID: 28635338
    [Abstract] [Full Text] [Related]

  • 8. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL.
    J Thromb Thrombolysis; 2019 Aug 01; 48(2):240-249. PubMed ID: 30924051
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, Masoudi FA, Hess PL, Maddox TM, Ho PM.
    BMC Cardiovasc Disord; 2017 Sep 02; 17(1):236. PubMed ID: 28865440
    [Abstract] [Full Text] [Related]

  • 14. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, Tang J, Mbuagbaw L, Witt DM, Crowther M, Thabane L, Levine MAH.
    Eur J Epidemiol; 2019 Feb 02; 34(2):173-190. PubMed ID: 29948370
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.
    BMJ; 2015 Apr 24; 350():h1857. PubMed ID: 25910928
    [Abstract] [Full Text] [Related]

  • 17. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
    Lip GYH, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Deitelzweig S.
    JAMA Netw Open; 2021 Aug 02; 4(8):e2120064. PubMed ID: 34398204
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I, Zhang Y, Saba S.
    Am J Cardiol; 2017 Nov 15; 120(10):1813-1819. PubMed ID: 28864318
    [Abstract] [Full Text] [Related]

  • 19. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.
    Curr Med Res Opin; 2017 Oct 15; 33(10):1745-1754. PubMed ID: 28849676
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims.
    Lip GYH, Noxon V, Kang A, Luo X, Atreja N, Han S, Cheng D, Jiang J, Abramovitz L, Deitelzweig S.
    J Thromb Thrombolysis; 2024 Aug 15; 57(6):1092-1102. PubMed ID: 38698197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.